The computational 3D drug-working model depicting the binding interactions between α-SYN aggregates and the drug candidates (D1, D3, D4, and D6) and EGCG at the Tyr39 and Lys43 residues. Credit: Science Advances (2024). DOI: 10.1126/sciadv.adk3700 Lewy body dementia (LBD) is a progressive neurodegenerative disease that shares traits with both Parkinson’s disease and Alzheimer’s disease but can be...
Tag: <span>Lewy body dementia</span>
Post
PET scans of the heart identify people at risk for Parkinson’s and Lewy body dementia
Reviewed by Lily Ramsey, LLM In a small study, researchers at the National Institutes of Health have found that positron emission tomography (PET) scans of the heart may identify people who will go on to develop Parkinson’s disease or Lewy body dementia among those at-risk for these diseases. The findings, published in the Journal of...
Post
PET scans may predict Parkinson’s disease and Lewy body dementia in at-risk individuals
by Erin Bryant, National Institutes of Health Heart and brain PET scans from a study participant who developed Parkinson’s disease support a “body first” progression. The top pair of PET scans image show low 18F-dopamine-derived radioactivity in the heart (right, with 13N-ammonia PET scan on left). Later, brain scans showed a loss of dopamine-producing neurons and...
Post
Successful Phase 2 clinical trial for neflamapimod in mild-to-moderate Lewy body dementia
by University of North Carolina at Chapel Hill School of Medicine EIP Pharma announced on October 6 that a phase 2 study in patients with mild-to-moderate Lewy body dementia (LBD) demonstrated an improvement in cognition as assessed by the Neuropsychological Test Battery (NTB). In the double-blind placebo-controlled study, patients receiving neflamapimod three times daily demonstrated significant...